Browsing Tag
VXB-241
3 posts
How much could Vicebio’s $1.15bn acquisition add to Sanofi’s RSV market share by 2030?
Can Sanofi’s $1.15B Vicebio deal help it win 10% of the RSV market by 2030? Analysts weigh in on how combination vaccines could change respiratory care.
Will Vicebio’s VXB-241 and VXB-251 give Sanofi an edge in older adult respiratory protection?
Can Sanofi’s VXB-241 and VXB-251 vaccines protect older adults better than single-pathogen RSV shots? Explore how they could reshape respiratory care.
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.